FMP
Halozyme Therapeutics, Inc.
HALO
NASDAQ
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
62.95 USD
0.68 (1.08%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
34.03M
72.83M
46.83M
78.59M
47.07M
57.9M
71.22M
87.61M
107.76M
132.56M
-
114
-35.71
67.84
-40.11
23.01
23.01
23.01
23.01
88.13M
-128.95M
-153.09M
-102.83M
-194.5M
-34.74M
-42.73M
-52.57M
-64.66M
-79.53M
258.95
-177.05
-326.92
-130.84
-413.2
-60
-60
-60
-60
-9.1M
-1.6M
-2.84M
-34.48M
-12.84M
-12.29M
-15.12M
-18.59M
-22.87M
-28.13M
-26.73
-2.19
-6.06
-43.87
-27.27
-21.22
-21.22
-21.22
-21.22
79.03M
-130.54M
-155.92M
-137.31M
-207.34M
-47.03M
-57.85M
-71.16M
-87.53M
-107.67M
34.49
75.04M
4.11
4.11
87.76M
2.59B
2.68B
3.28
96.72
14.27
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
34.03M
72.83M
46.83M
78.59M
47.07M
57.9M
71.22M
87.61M
107.76M
132.56M
88.13M
-128.95M
-153.09M
-102.83M
-194.5M
-34.74M
-42.73M
-52.57M
-64.66M
-79.53M
-9.1M
-1.6M
-2.84M
-34.48M
-12.84M
-12.29M
-15.12M
-18.59M
-22.87M
-28.13M
79.03M
-130.54M
-155.92M
-137.31M
-207.34M
-47.03M
-57.85M
-71.16M
-87.53M
-107.67M
14.27
14.27
14.27
14.27
14.27
-41.16M
-44.3M
-47.68M
-51.33M
-55.25M
-239.72M
14.27
-109.82M
-894.7M
-459.12M
-698.84M
-32.49M
-666.35M
75.04M
-8.88
-8.88 4.884%